{"analyses":[{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.51","estimateComment":"Reference level = low EGFR","groupDescription":"Progression-free survival is compared between favorable risk and unfavorable risk groups.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.60","paramType":"Hazard Ratio (HR)","paramValue":"1.09","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.76","estimateComment":"Reference level = low EGFR","groupDescription":"Overall survival is compared between favorable risk and unfavorable risk groups.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.37","paramType":"Hazard Ratio (HR)","paramValue":"1.19","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","estimateComment":"Reference level = low EGFR","groupDescription":"Local-regional failure","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.76","paramType":"Hazard Ratio (HR)","paramValue":"0.93","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.9","upperLimit":"69.4","value":"63.5"},{"groupId":"OG001","lowerLimit":"51.7","upperLimit":"67.8","value":"60.3"}]}],"title":"Progression-free survival (PFS)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.6","upperLimit":"81.7","value":"76.7"},{"groupId":"OG001","lowerLimit":"66.9","upperLimit":"81.4","value":"75.0"}]}],"title":"Overall survival (OS)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.6","upperLimit":"27.3","value":"21.7"},{"groupId":"OG001","lowerLimit":"13.1","upperLimit":"26.1","value":"19.2"}]}],"title":"Loco-regional failure (LRF)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"EGFR expression is categorized as high (\\>/=80%) and low (\\<80%) in order to compare outcome by favorable and unfavorable risk group, per protocol. Times are measured from randomization. Overall survival is defined as time from randomization to date of death from any cause. PFS is time to loco-regional progression (LRP), distant disease progression (DDP), or death. LRF is time to LRP, DDP, or death, with DDP considered a competing risk. Patients last known to be alive without event are censored at the date of last contact. LRP is defined as an estimated increase in the size of the tumor (product of the perpendicular diameters of the two largest dimensions) of greater than 25%, taking as reference the smallest value of all previous measurements or appearance of new areas of malignant disease. DDP is defined as clear evidence of distant metastases. Three-year LRF rates were estimated by the cumulative incidence method. Three-year PFS and OS rates were estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Less than 80% EGFR","id":"OG000","title":"Low EGFR"},{"description":"Greater than or equal to 80% EGFR","id":"OG001","title":"High EGFR"}],"paramType":"NUMBER","populationDescription":"Randomized eligible patients with follow-up and EGFR data.","reportingStatus":"POSTED","timeFrame":"From randomization until 434 failures have occurred, approximately 5 years from start of study. (Patients are followed until death or study termination, whichever occurs first.)","title":"Correlation of Expression of Epidermal Growth Factor Receptor (EGFR) With PFS, OS, and LRF","type":"SECONDARY","unitOfMeasure":"percentage of participants"}